PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

Cited by (1,079)

Items 401–500 of 1,079

1. Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups
   Tjalling Bosse, Remi A. Nout, Jessica Nell McAlpine, Melissa K. McConechy, Heidi M. Britton, Yaser R. Hussein, Carlene Gonzalez, Raji Ganesan, Jane C. Steele, Beth T. Harrison et al. · 2018 · The American Journal of Surgical Pathology
2. Targeting programmed cell death -1 (PD-1) and ligand (PD-L1): A new era in cancer active immunotherapy
   Constantinidou, Anastasia, Alifieris, Constantinos, Trafalis, Dimitrios T. · 2019 · Pharmacology & Therapeutics
3. Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNA
   Kasmintan A. Schrader, Donavan T. Cheng, Joseph Vijai, Meera Prasad, Michael Francis Walsh, Ahmet Zehir, Ai Ni, Tinu Thomas, Ryma Benayed, Asad M. Ashraf et al. · 2015 · JAMA Oncology
4. Implementing TMB measurement in clinical practice: considerations on assay requirements
   Reinhard Büttner, John W. Longshore, Fernando López‐Ríos, Sabine Merkelbach‐Bruse, Nicola Normanno, Étienne Rouleau, Frederique Madeleine Penault-Llorca · 2019 · ESMO Open
5. Deficient mismatch repair/microsatellite unstable colorectal cancer: Diagnosis, prognosis and treatment
   Julien Taı̈eb, Magali Svrcek, Romain Cohen, Debora Basile, David Tougeron, Jean–Marc Phelip · 2022 · European Journal of Cancer
6. Synergistic Transcutaneous Immunotherapy Enhances Antitumor Immune Responses through Delivery of Checkpoint Inhibitors
   Yanqi Ye, Jinqiang Wang, Quanyin Hu, Gabrielle M. Hochu, Hongliang Xin, Chao Wang, Zhen Gu · 2016 · ACS Nano
7. High response rate to PD-1 blockade in desmoplastic melanomas
   Eroglu, Zeynep, Zaretsky, Jesse M., Hu-Lieskovan, Siwen, Kim, Dae Won, Algazi, Alain, Johnson, Douglas B., Liniker, Elizabeth, Ben Kong, Munhoz, Rodrigo, Rapisuwon, Suthee et al. · 2018 · Nature
8. Nanoscale metal-organic frameworks enhance radiotherapy to potentiate checkpoint blockade immunotherapy
   Kaiyuan Ni, Guangxu Lan, Christina Chan, Bryan Quigley, Kuangda Lu, Theint Aung, Nining Guo, Patrick J. La Rivière, Ralph R. Weichselbaum, Wenbin Lin · 2018 · Nature Communications
9. From mice to humans: developments in cancer immunoediting
   Teng, Michele W.L., Galon, Jerome, Fridman, Wolf-Herman, Smyth, Mark J. · 2015 · Journal of Clinical Investigation
10. CHECKPOINT INHIBITOR IMMUNE THERAPY: Systemic Indications and Ophthalmic Side Effects
    Dalvin, Lauren A., Shields, Carol L., Orloff, Marlana, Sato, Takami, Shields, Jerry A. · 2018 · Retina
11. Rectal and colon cancer: Not just a different anatomic site
    K Tamás, Annemiek Walenkamp, Elisabeth G.E. de Vries, Marcel A.T.M. van Vugt, Regina G. H. Beets‐Tan, Boudewijn van Etten, Derk Jan A. de Groot, Geke A.P. Hospers · 2015 · Cancer Treatment Reviews
12. PARP Inhibitors: Extending Benefit Beyond BRCA -Mutant Cancers
    Patrick Glen Pilie, Carl Michael Gay, Lauren A. Byers, Mark J. O’Connor, Timothy Anthony Yap · 2019 · Clinical Cancer Research
13. Alterations of DNA damage response pathway: Biomarker and therapeutic strategy for cancer immunotherapy
    Minlin Jiang, Keyi Jia, Lei Wang, Wei Li, Bin Chen, Yu Liu, Hao Wang, Sha Zhao, Yayi He, Caicun Zhou · 2021 · Acta Pharmaceutica Sinica B
14. Antigen presentation in cancer — mechanisms and clinical implications for immunotherapy
    Kailin Yang, Ahmed Halima, Timothy An-thy Chan · 2023 · Nature Reviews Clinical Oncology
15. PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer
    Chabanon, Roman M., Muirhead, Gareth, Krastev, Dragomir B., Adam, Julien, Morel, Daphné, Garrido, Marlène, Lamb, Andrew, Hénon, Clémence, Dorvault, Nicolas, Rouanne, Mathieu et al. · 2019 · Journal of Clinical Investigation
16. Tertiary lymphoid structures and B cells: An intratumoral immunity cycle
    Wolf H. Fridman, Maxime Meylan, Guilhem Pupier, Anne Calvez, Isaias Hernández-Verdín, Catherine Sautès‐Fridman · 2023 · Immunity
17. The plasticity of DNA replication forks in response to clinically relevant genotoxic stress
    Matteo Berti, David Cortez, Massimo Lopes · 2020 · Nature Reviews Molecular Cell Biology
18. Limitations and opportunities of technologies for the analysis of cell-free DNA in cancer diagnostics
    Ping Song, Lucia Ruojia Wu, Yan Helen Yan, Jinny Xuemeng Zhang, Tianqing Chu, Lawrence N. Kwong, Abhijit A. Patel, David Yu Zhang · 2022 · Nature Biomedical Engineering
19. Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy
    Weijie Ma, Barbara M. Gilligan, Jianda D. Yuan, Tianhong Li · 2016 · Journal of Hematology & Oncology
20. Differential pre-malignant programs and microenvironment chart distinct paths to malignancy in human colorectal polyps
    Bob Chen, Cherie’ R. Scurrah, Eliot T. McKinley, Alan J. Simmons, Marisol A Ramirez-Solano, Xiangzhu Zhu, Nicholas O. Markham, Cody N. Heiser, Paige N. Vega, Andrea Rolong et al. · 2021 · Cell
21. Pan-cancer deconvolution of tumour composition using DNA methylation
    Chakravarthy, Ankur, Furness, Andrew, Joshi, Kroopa, Ghorani, Ehsan, Ford, Kirsty, Ward, Matthew J., King, Emma V., Lechner, Matt, Marafioti, Teresa, Quezada, Sergio A. et al. · 2018 · Nature Communications
22. Clinical trial design in the era of precision medicine
    Elena Fountzilas, Apostolia Maria Tsimberidou, Henry Hiep Vo, Razelle Kurzrock · 2022 · Genome Medicine
23. NCCN Guidelines Updates: Pancreatic Cancer.
    Margaret A. Tempero · 2019 · PubMed
24. PD ‐L1 expression is mainly regulated by interferon gamma associated with JAK ‐ STAT pathway in gastric cancer
    Kousaku Mimura, Jun Liang Teh, Hirokazu Okayama, Kensuke Shiraishi, Ley‐Fang Kua, Vivien Koh, Duane T. Smoot, Hassan Ashktorab, Takahiro Oike, Yoshiyuki Suzuki et al. · 2017 · Cancer Science
25. T cell receptor‐based cancer immunotherapy: Emerging efficacy and pathways of resistance
    Smita S. Chandran, Christopher Austin Klebanoff · 2019 · Immunological Reviews
26. Mucinous colorectal adenocarcinoma: clinical pathology and treatment options
    Cong Luo, Shuyi Cen, Guojun Ding, Wei Wu · 2019 · 癌症：英文版
27. PD-L1
    Anthousa Kythreotou, Abdul Siddique, Francesco Angelo Mauri, Mark Bower, David James Pinato · 2017 · Journal of Clinical Pathology
28. Cancer organoids 2.0: modelling the complexity of the tumour immune microenvironment
    Roel Polak, Elisa Zhang, Calvin Jay Kuo · 2024 · Nature reviews. Cancer
29. Biomarker-guided therapy for colorectal cancer: strength in complexity
    Sveen, Anita, Kopetz, Scott, Lothe, Ragnhild A. · 2020 · Nature Reviews Clinical Oncology
30. Biomarkers of response to PD-1/PD-L1 inhibition
    Saman Maleki Vareki, Carmen Garrigós, Ignacio Durán · 2017 · Critical Reviews in Oncology/Hematology
31. Microbiota-specific T follicular helper cells drive tertiary lymphoid structures and anti-tumor immunity against colorectal cancer
    Overacre-Delgoffe, Abigail E., Bumgarner, Hannah J., Cillo, Anthony R., Burr, Ansen H.P., Tometich, Justin T., Bhattacharjee, Amrita, Bruno, Tullia C., Vignali, Dario A.A., Hand, Timothy W. · 2021 · Immunity
32. Emerging Opportunities and Challenges in Cancer Immunotherapy
    Theresa L. Whiteside, Sandra Demaria, Maria Esperanza Rodriguez-Ruiz, Hassane M. Zarour, Ignacio Melero · 2016 · Clinical Cancer Research
33. Genetic profiling of hepatocellular carcinoma using next-generation sequencing
    Kornelius Schulze, Jean‐Charles Nault, Augusto Villanueva · 2016 · Journal of Hepatology
34. DNA Damage and Cancer Immunotherapy: A STING in the Tale
    Timo Reisländer, Florian J. Groelly, Madalena Tarsounas · 2020 · Molecular Cell
35. Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: a proof-of-concept study
    Cabel, L., Riva, F., Servois, V., Livartowski, A., Daniel, C., Rampanou, A., Lantz, O., Romano, E., Milder, M., Buecher, B. et al. · 2017 · Annals of Oncology
36. First-in-human phase I study of the oral inhibitor of indoleamine 2,3-dioxygenase-1 epacadostat (INCB024360) in patients with advanced solid malignancies
    Beatty, Gregory L., O'Dwyer, Peter J., Clark, Jason, Shi, Jack G., Bowman, Kevin J., Scherle, Peggy A., Newton, Robert C., Schaub, Richard, Maleski, Janet, Leopold, Lance et al. · 2017 · Clinical Cancer Research
37. Performance evaluation for rapid detection of pan-cancer microsatellite instability with MANTIS
    Esko Antero Kautto, Russell Bonneville, Jharna Miya, Lianbo Yu, Melanie A. Krook, Julie W. Reeser, Sameek Roychowdhury · 2016 · Oncotarget
38. Homology-Directed Repair and the Role of BRCA1, BRCA2, and Related Proteins in Genome Integrity and Cancer
    Chun-Chin Chen, Weiran Feng, Pei Xin Lim, Elizabeth M. Kass, Maria Jasin · 2017 · Annual Review of Cancer Biology
39. Tumor mutational burden quantification from targeted gene panels: major advancements and challenges
    Laura Fancello, Sara Gandini, Pier Giuseppe Pelicci, Luca Mazzarella · 2019 · Journal for ImmunoTherapy of Cancer
40. Tissue-specific tumorigenesis: context matters
    Günter Schneider, Marc Schmidt‐Supprian, Roland Rad, Dieter Saur · 2017 · Nature reviews. Cancer
41. The evolving role of microsatellite instability in colorectal cancer: A review
    Fabio Gelsomino, Monica Barbolini, Andrea Spallanzani, Giuseppe Pugliese, Stefano Cascinu · 2016 · Cancer Treatment Reviews
42. Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial
    Huabin Hu, Liang Kang, Jianwei Zhang, Zehua Wu, Hui Wang, Meijin Huang, Ping Lan, Xiaojian Wu, Chao Wang, Wuteng Cao et al. · 2021 · The Lancet. Gastroenterology & hepatology
43. Immunity, Hypoxia, and Metabolism–the Ménage à Trois of Cancer: Implications for Immunotherapy
    Riera-Domingo, Carla, Audigé, Annette, Granja, Sara, Cheng, Wan-Chen, Ho, Ping-Chih, Baltazar, Fátima, Stockmann, Christian, Mazzone, Massimiliano · 2020 · Physiological Reviews
44. Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: A retrospective, pooled biomarker study
    Domingo, Enric, Freeman-Mills, Luke, Rayner, Emily, Glaire, Mark, Briggs, Sarah, Vermeulen, Louis, Fessler, Evelyn, Medema, Jan Paul, Boot, Arnoud, Morreau, Hans et al. · 2016 · The Lancet Gastroenterology & Hepatology
45. Natural and therapy-induced immunosurveillance in breast cancer
    Guido Kroemer, Laura Senovilla, Lorenzo Galluzzi, Fabrice André, Laurence Zitvogel · 2015 · Nature Medicine
46. Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers
    Sarah Derks, Xiaoyun Liao, Anna Maria Chiaravalli, Xinsen Xu, Maria Constanza Camargo, Enrico Solcia, Fausto Sessa, Tania Fleitas, Gordon James Freeman, Scott J. Rodig et al. · 2016 · Oncotarget
47. Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy
    Aaron Michael Goodman, Ethan S. Sokol, Garrett Michael Frampton, Scott Michael Lippman, Razelle Kurzrock · 2019 · Cancer Immunology Research
48. The immune system and cancer evasion strategies: therapeutic concepts
    Muenst, S., Läubli, H., Soysal, S. D., Zippelius, A., Tzankov, A., Hoeller, S. · 2016 · Journal of Internal Medicine
49. Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma
    Robert Montal, Daniela Sia, Carla Montironi, Wei Qiang Leow, Roger Esteban-Fabró, Roser Pinyol, Miguel Torres‐Martín, Laia Bassaganyas, Agrin Moeini, Judit Peix et al. · 2020 · Journal of Hepatology
50. Atezolizumab and nab -Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study
    Leisha A. Emens, Luciana Lorena Molinero, Sherene Loi, Hope S. Rugo, Andreas Schneeweiß, Veronique C Dieras, Hiroji Iwata, Carlos H. Barrios, Marina N. Nechaeva, Anh Nguyen-Duc et al. · 2021 · JNCI Journal of the National Cancer Institute
51. Characteristics of Early-Onset vs Late-Onset Colorectal Cancer
    REACCT Collaborative, Alexandra M. Zaborowski, Ahmed Abdile, Michel Adamina, Felix Aigner, Laura d’Allens, Caterina Allmer, Andrea Álvarez, Rocío Anula, Mihailo Andric et al. · 2021 · JAMA Surgery
52. Immunologic Strategies in Pancreatic Cancer: Making Cold Tumors Hot
    Nicholas A. Ullman, Paul R. Burchard, Richard Francis Dunne, David C. Linehan · 2022 · Journal of Clinical Oncology
53. LAYN Is a Prognostic Biomarker and Correlated With Immune Infiltrates in Gastric and Colon Cancers
    Jinghua Pan, Hong Ke Zhou, Laura M. Cooper, Huang Jin-lian, Shengbin Zhu, Xiao-xu Zhao, Hui Ding, Yun-long Pan, Lijun Rong · 2019 · Frontiers in Immunology
54. Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy
    Davide Ciardiello, Pietro Paolo Vitiello, Claudia Cardone, Giulia Martini, Teresa Troiani, Erika Martinelli, Fortunato Ciardiello · 2019 · Cancer Treatment Reviews
55. The efficacy of anti‐PD‐1 agents in acral and mucosal melanoma
    Alexander Noor Shoushtari, Rodrigo Ramella Munhoz, Deborah Kuk, Patrick Alexander Ott, Douglas Buckner Johnson, Katy K. Tsai, Suthee Rapisuwon, Zeynep Eroglu, Ryan Joseph Sullivan, Jason J. Luke et al. · 2016 · Cancer
56. Antigen presentation and tumor immunogenicity in cancer immunotherapy response prediction
    Shixiang Wang, Zaoke He, Xuan Wang, Huimin Li, Xuesong Liu · 2019 · eLife
57. Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer
    Anniina Färkkilä, D. Gulhan, Julia Casado, Connor A. Jacobson, Huy Q. Nguyen, Bose S. Kochupurakkal, Zoltan Maliga, Clarence Yapp, Yu‐An Chen, Denis Schapiro et al. · 2020 · Nature Communications
58. Targeting the DNA damage response in immuno-oncology: developments and opportunities
    Roman M. Chabanon, Mathieu Rouanne, Christopher J. Lord, Jean‐Charles Soria, Philippe Pasero, Sophie C. Postel-Vinay · 2021 · Nature reviews. Cancer
59. Molecular Genetics of Endometrial Carcinoma
    Daphne W. Bell, Lora H. Ellenson · 2018 · Annual Review of Pathology Mechanisms of Disease
60. PD-1 and PD-L1 antibodies in cancer: current status and future directions
    Arjun Vasant Balar, Jeffrey S. Weber · 2017 · Cancer Immunology Immunotherapy
61. Colorectal liver metastasis: molecular mechanism and interventional therapy
    Zhou, Hui, Liu, Zhongtao, Wang, Yongxiang, Wen, Xiaoyong, Amador, Eric H., Yuan, Liqin, Ran, Xin, Xiong, Li, Ran, Yuping, Chen, Wei et al. · 2022 · Signal Transduction and Targeted Therapy
62. Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial
    Aparna R. Parikh, Annamária Szabolcs, Jill N. Allen, Jeffrey William Clark, Jennifer Yon-Li Wo, Michael J. Raabe, Hannah L. Thel, David Hoyos, Arnav Mehta, Sanya Arshad et al. · 2021 · Nature Cancer
63. TRK inhibitors in TRK fusion-positive cancers
    Alexander Edward Dela Cruz Drilon · 2019 · Annals of Oncology
64. Targeting immune checkpoints potentiates immunoediting and changes the dynamics of tumor evolution
    Mirjana Efremova, Dietmar Rieder, Victoria Klepsch, Pornpimol Charoentong, Francesca Finotello, Hubert Hackl, Natascha Hermann‐Kleiter, Martin Löwer, Gottfried Baier, Anne Krogsdam et al. · 2017 · Nature Communications
65. Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations
    Ioannis Zerdes, Alexios Matikas, Jonas C. S. Bergh, George Z. Rassidakis, Theodoros Foukakis · 2018 · Oncogene
66. Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy
    Shumei Kato, Ki Hwan Kim, Hyo Jeong Lim, Amélie Boichard, Mina Nikanjam, Elizabeth Weihe, Dennis John Kuo, Ramez Nassef Eskander, Aaron Michael Goodman, Natalie Galanina et al. · 2020 · Nature Communications
67. WNT Signaling and Colorectal Cancer
    Emma M. Schatoff, Benjamin I. Leach, Lukas E. Dow · 2017 · Current Colorectal Cancer Reports
68. Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers
    Horak, Peter, Heining, Christoph, Kreutzfeldt, Simon, Hutter, Barbara, Mock, Andreas, Hüllein, Jennifer, Fröhlich, Martina, Uhrig, Sebastian, Jahn, Arne, Rump, Andreas et al. · 2021 · Cancer Discovery
69. Immunogenomics of Hypermutated Glioblastoma: A Patient with Germline POLE Deficiency Treated with Checkpoint Blockade Immunotherapy
    Tanner Michael Johanns, Christopher A. Miller, Ian G. Dorward, Christina I. Tsien, Edward F. Chang, Arie Perry, Ravindra Uppaluri, Cole Ferguson, Robert E. Schmidt, Sonika M Dahiya et al. · 2016 · Cancer Discovery
70. Mutational signatures reveal the dynamic interplay of risk factors and cellular processes during liver tumorigenesis
    Éric Letouzé, Jayendra Shinde, Victor Renault, Gabrielle Couchy, Jean‐Frédéric Blanc, Emmanuel Tubacher, Quentin Bayard, Delphine Bacq, Vincent Meyer, Jérémy Semhoun et al. · 2017 · Nature Communications
71. PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
    Zijun Yidan Xu-Monette, Mingzhi Zhang, Jianyong Li, Ken H. Young · 2017 · Frontiers in Immunology
72. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS
    Kei Muro, Florian Lordick, Takahiro Tsushima, George E. Pentheroudakis, Eishi Baba, Z. Lu, Byoung Chul Cho, Ibtisam Muhamad Nor, MATTHEW MA‐TAI NG, L -T Chen et al. · 2018 · Annals of Oncology
73. Unique Neoantigens Arise from Somatic Mutations in Patients with Gastrointestinal Cancers
    Maria R. Parkhurst, Paul F. Robbins, Eric Tran, Todd D. Prickett, Jared J. Gartner, Lee Jia, Gabriel D. Ivey, Yong F. Li, Mona El‐Gamil, Almin Lalani et al. · 2019 · Cancer Discovery
74. Immunotherapy, Inflammation and Colorectal Cancer
    Charles Robert Lichtenstern, Rachael Katie Ngu, Shabnam Shalapour, Michael Karin · 2020 · Cells
75. Pembrolizumab for the treatment of non-small cell lung cancer
    Sung Hee Lim, Jong‐Mu Sun, Se‐Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung‐Ju Ahn · 2016 · Expert Opinion on Biological Therapy
76. PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes
    Matthew W. Rosenbaum, Jacob R. Bledsoe, Vicente Morales‐Oyarvide, Tiffany G. Huynh, Mari A. Mino-Kenudson · 2016 · Modern Pathology
77. Personalized Medicine: Recent Progress in Cancer Therapy
    Valentina Gambardella, Noelia Tarazona, Juan Miguel Cejalvo, Pasquale Lombardi, Marisol Huerta, Susana Roselló, Tania Fleitas, Desamparados Roda, Andrès M.R. Cervantes · 2020 · Cancers
78. PD-L1 is an independent prognostic predictor in gastric cancer of Western patients
    Christine Böger, Hans‐Michael Behrens, Micaela Mathiak, Sandra Krüger, Holger Kalthoff, Christoph Röcken · 2016 · Oncotarget
79. Resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives
    Jin‐Yu Sun, Dengke Zhang, Songquan Wu, Min Xu, Xiao Zhou, Xiaojie Lu, Jiansong Ji · 2020 · Biomarker Research
80. Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities
    Hack, Stephen P., Zhu, Andrew X., Wang, Yulei · 2020 · Frontiers in Immunology
81. Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients
    Karachaliou, Niki, Gonzalez-Cao, Maria, Crespo, Guillermo, Drozdowskyj, Ana, Aldeguer, Erika, Gimenez-Capitan, Ana, Teixido, Cristina, Molina-Vila, Miguel Angel, Viteri, Santiago, De Los Llanos Gil, Maria et al. · 2018 · Therapeutic Advances in Medical Oncology
82. High-dose vitamin C enhances cancer immunotherapy
    Magrì, Alessandro, Germano, Giovanni, Lorenzato, Annalisa, Lamba, Simona, Chilà, Rosaria, Montone, Monica, Amodio, Vito, Ceruti, Tommaso, Sassi, Francesco, Arena, Sabrina et al. · 2020 · Science Translational Medicine
83. DNA Sensing in Mismatch Repair-Deficient Tumor Cells Is Essential for Anti-tumor Immunity
    Lu, Changzheng, Guan, Junhong, Lu, Steve, Jin, Qihuang, Rousseau, Benoit, Lu, Tianshi, Stephens, Dennis, Zhang, Hongyi, Zhu, Jiankun, Yang, Mingming et al. · 2021 · Cancer Cell
84. Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma
    Ashton Anthony Connor, Robert Edward Denroche, Gun Ho Jang, Lee E. Timms, Sangeetha N. Kalimuthu, Iris Selander, Treasa A. McPherson, Gavin W. Wilson, Michelle Chan‐Seng‐Yue, Ivan Borozan et al. · 2016 · JAMA Oncology
85. Lynch Syndrome–Associated Colorectal Cancer
    Frank A. Sinicrope · 2018 · New England Journal of Medicine
86. Single-cell analysis of pancreatic ductal adenocarcinoma identifies a novel fibroblast subtype associated with poor prognosis but better immunotherapy response
    Yu Wang, Yiyi Liang, Haiyan Xu, Xiao Zhang, Tiebo Mao, Jiujie Cui, Jiayu Yao, Yongchao Wang, Feng Jiao, Xiuying Xiao et al. · 2021 · Cell Discovery
87. Mismatch Repair Deficiency and Response to Immune Checkpoint Blockade
    Valerie Lee, Adrian Gerard Murphy, Dung Thi Le, Luis Alberto Diaz · 2016 · The Oncologist
88. Reduced m6A modification predicts malignant phenotypes and augmented Wnt/PI3K‐Akt signaling in gastric cancer
    Cheng Zhang, Mengqi Zhang, Sai Ge, Wenwen Huang, Xiaoting Lin, Jing Xing Gao, Jifang Gong, Lin Shen · 2019 · Cancer Medicine
89. Patient-centric trials for therapeutic development in precision oncology
    Andrew Victor Biankin, Steven Piantadosi, Simon J. Hollingsworth · 2015 · Nature
90. DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma
    Min Yuen Teo, Richard Martin Bambury, Emily Craig Zabor, Emmet Jordan, Hikmat A Al‐Ahmadie, Mariel Elena Boyd, Nancy Bouvier, Stephanie Anne Mullane, Eugene K. Cha, Nitin Roper et al. · 2017 · Clinical Cancer Research
91. Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities
    Pauken, Kristen E., Dougan, Michael, Rose, Noel R., Lichtman, Andrew H., Sharpe, Arlene H. · 2019 · Trends in Immunology
92. Upfront FOLFOXIRI plus Bevacizumab with or without Atezolizumab in the Treatment of Patients with Metastatic Colorectal Cancer (AtezoTRIBE): A Multicentre, Open-Label, Randomised, Controlled, Phase 2 Trial
    Antoniotti, Carlotta, Rossini, Daniele, Pietrantonio, Filippo, Catteau, Aurélie, Salvatore, Lisa, Lonardi, Sara, Boquet, Isabelle, Tamberi, Stefano, Marmorino, Federica, Moretto, Roberto et al. · 2022 · The Lancet Oncology
93. Tumor immune microenvironment and immune checkpoint inhibitors in esophageal squamous cell carcinoma
    Yoshifumi Baba, Daichi Nomoto, Kazuo Okadome, Takatsugu Ishimoto, Masaaki Iwatsuki, Yuji Miyamoto, Naoya Yoshida, Hideo Baba · 2020 · Cancer Science
94. Colorectal liver metastases: Current management and future perspectives
    Jack L. Martin, Angelica Petrillo, Elizabeth C. Smyth, Nadeem Shaida, Samir A. Khwaja, H.K. Cheow, Adam Duckworth, Paula Maria Heister, Raaj Praseedom, Asif Jah et al. · 2020 · World Journal of Clinical Oncology
95. Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II–Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3
    Yong‐Chen Lu, Linda L. Parker, Tangying Lu, Zhili Zheng, Mary Ann Toomey, Donald Edward White, Xin Yao, Yong F. Li, Paul F. Robbins, Steven A. Feldman et al. · 2017 · Journal of Clinical Oncology
96. Mutational signatures: emerging concepts, caveats and clinical applications
    Ching Chiek Koh, Andrea Degasperi, Xueqing Zou, Sophie Momen, Serena Nik‐Zainal · 2021 · Nature reviews. Cancer
97. A Comprehensive Immunologic Portrait of Triple-Negative Breast Cancer
    Liu, Zhixian, Li, Mengyuan, Jiang, Zehang, Wang, Xiaosheng · 2018 · Translational Oncology
98. Small Bowel Adenocarcinoma, Version 1.2020, NCCN Clinical Practice Guidelines in Oncology
    Al B. Benson, Alan Paul Venook, Mahmoud M. Al-Hawary, Mustafa A. Arain, Yi‐Jen Chen, Kristen Keon Ciombor, Stacey A. Cohen, Harry S. Cooper, Dustin A. Deming, Ignacio Garrido‐Laguna et al. · 2019 · Journal of the National Comprehensive Cancer Network
99. The genomic landscape of breast cancer and its interaction with host immunity
    Stephen James Luen, Balaji Virassamy, Peter Stephen Savas, Roberto Salgado, Sherene Loi · 2016 · The Breast
100. Colorectal Cancer Liver Metastasis: Evolving Paradigms and Future Directions
     Luai R. Zarour, Sudarshan Anand, Kevin G. Billingsley, William H. Bisson, Andrea Cercek, Michael F. Clarke, Lisa M. Coussens, Charles E. Gast, Cristina B. Geltzeiler, Lissi Hansen et al. · 2017 · Cellular and Molecular Gastroenterology and Hepatology